Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Acrivon Therapeutics, Inc. (ACRV) had Normalized Income after Taxes of $-17.96M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-17.96M |
|
-- |
|
-- |
|
$18.67M |
|
$-18.67M |
|
$0.70M |
|
$-17.96M |
|
$-17.96M |
|
$-17.96M |
|
$-17.96M |
|
$-17.96M |
|
|
Normalized Income after Taxes |
$-17.96M |
$-18.67M |
|
$-18.20M |
|
41.84M |
|
41.84M |
|
$-0.43 |
|
$-0.43 |
|
| Balance Sheet Financials | |
$91.49M |
|
$4.25M |
|
$7.60M |
|
$99.09M |
|
$11.45M |
|
-- |
|
$0.98M |
|
$12.43M |
|
$86.67M |
|
$86.67M |
|
$86.67M |
|
42.85M |
|
| Cash Flow Statement Financials | |
$-35.40M |
|
$28.07M |
|
$7.24M |
|
$41.70M |
|
$41.61M |
|
$-0.09M |
|
$4.39M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.99 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-35.50M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-20.73% |
|
-20.73% |
|
-18.13% |
|
-20.73% |
|
$2.02 |
|
$-0.85 |
|
$-0.85 |
|